Published in J Immunol on March 28, 2014
Adjuvant for vaccine immunotherapy of cancer - focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci (2015) 0.84
Cell Signaling Pathways That Regulate Antigen Presentation. J Immunol (2016) 0.77
A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells. Hum Vaccin Immunother (2015) 0.77
A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population. Oncotarget (2016) 0.75
A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms. Sci Rep (2015) 0.75
The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells. Front Immunol (2017) 0.75
Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity (1997) 5.44
A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (1995) 4.64
ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature (2003) 4.18
Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science (2005) 4.12
Phagosomes are competent organelles for antigen cross-presentation. Nature (2003) 3.97
T-cell engagement of dendritic cells rapidly rearranges MHC class II transport. Nature (2002) 3.93
Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell (2006) 3.83
Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol (2008) 3.08
Rab7 associates with early endosomes to mediate sorting and transport of Semliki forest virus to late endosomes. PLoS Biol (2005) 2.95
p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. J Cell Biol (2006) 2.15
Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity (2004) 2.13
Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol (2007) 1.81
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 1.78
Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol (2005) 1.72
Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood (2012) 1.43
The role of endoplasmic reticulum-associated aminopeptidase 1 in immunity to infection and in cross-presentation. J Immunol (2007) 1.33
Lipoteichoic acid and toll-like receptor 2 internalization and targeting to the Golgi are lipid raft-dependent. J Biol Chem (2004) 1.31
Extracellular signal-regulated kinase regulates clathrin-independent endosomal trafficking. Mol Biol Cell (2005) 1.30
Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 1.23
Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol (2000) 1.14
Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9. J Immunol (2010) 1.13
Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood (2011) 1.06
IL-6 and IL-12 specifically regulate the expression of Rab5 and Rab7 via distinct signaling pathways. EMBO J (2006) 1.04
Endosomal targeting of MEK2 requires RAF, MEK kinase activity and clathrin-dependent endocytosis. Traffic (2008) 1.04
Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res (1998) 1.03
Cross-talk between the endocytic pathway and the endoplasmic reticulum in cross-presentation by MHC class I molecules. Curr Opin Immunol (2006) 1.00
A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine (2009) 0.98
Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity. PLoS One (2010) 0.97
The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J Immunol (2010) 0.97
Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS (2010) 0.97
The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation. PLoS Pathog (2010) 0.96
Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation. Eur J Immunol (2000) 0.96
CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8α+ dendritic cells [corrected]. J Immunol (2010) 0.95
A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol Immunol (2010) 0.94
TLR and nucleotide-binding oligomerization domain-like receptor signals differentially regulate exogenous antigen presentation. J Immunol (2011) 0.93
Overexpression of rab7 enhances the kinetics of antigen processing and presentation with MHC class II molecules in B cells. Int Immunol (2002) 0.92
TLR2 mediates phagocytosis and autophagy through JNK signaling pathway in Staphylococcus aureus-stimulated RAW264.7 cells. Cell Signal (2014) 0.91
The synthetic analogue of mycoplasmal lipoprotein FSL-1 induces dendritic cell maturation through Toll-like receptor 2. FEMS Immunol Med Microbiol (2006) 0.90
The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens. Eur J Immunol (2010) 0.89
A proteasome-dependent, TAP-independent pathway for cross-presentation of phagocytosed antigen. EMBO Rep (2011) 0.88
The Toll-like receptor 2 (TLR2) ligand FSL-1 is internalized via the clathrin-dependent endocytic pathway triggered by CD14 and CD36 but not by TLR2. Immunology (2010) 0.87
Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study. Clin Vaccine Immunol (2008) 0.85
Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. Clin Exp Immunol (2011) 0.85
TLR9 activation increases TAP-independent vesicular MHC class I processing in vivo. Scand J Immunol (2009) 0.84
HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination. AIDS Res Hum Retroviruses (2007) 0.84
The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen. Immunology (2012) 0.79
Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses. Vaccine (2008) 0.78
Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer. Acta Pharmacol Sin (2007) 0.77
Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine (2011) 1.83
Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother (2005) 1.65
Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J Leukoc Biol (2007) 1.52
Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis (2012) 1.31
Heterodimeric complexes of Hop2 and Mnd1 function with Dmc1 to promote meiotic homolog juxtaposition and strand assimilation. Proc Natl Acad Sci U S A (2004) 1.30
Enhancement of wound healing by human multipotent stromal cell conditioned medium: the paracrine factors and p38 MAPK activation. Cell Transplant (2010) 1.24
Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology (2011) 1.23
Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One (2012) 1.12
Immunological study of HA1 domain of hemagglutinin of influenza H5N1 virus. Biochem Biophys Res Commun (2009) 1.11
Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS One (2011) 1.10
Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One (2013) 1.10
DC-SIGN mediates avian H5N1 influenza virus infection in cis and in trans. Biochem Biophys Res Commun (2008) 1.07
A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect (2008) 1.05
Production of EV71 vaccine candidates. Hum Vaccin Immunother (2012) 1.05
CoS acicular nanorod arrays for the counter electrode of an efficient dye-sensitized solar cell. ACS Nano (2012) 1.04
An improved SUMO fusion protein system for effective production of native proteins. Protein Sci (2008) 1.03
Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines. Vaccine (2008) 0.99
Human SCARB2-mediated entry and endocytosis of EV71. PLoS One (2012) 0.98
A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine (2009) 0.98
A triterpenoid methyl antcinate K isolated from Antrodia cinnamomea promotes dendritic cell activation and Th2 differentiation. Eur J Immunol (2009) 0.95
Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process. J Virol Methods (2011) 0.94
A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol Immunol (2010) 0.94
Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One (2010) 0.94
Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine (2006) 0.93
Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS One (2012) 0.92
Self-polymerization of archaeal RadA protein into long and fine helical filaments. Biochem Biophys Res Commun (2004) 0.92
Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol (2012) 0.91
Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates. J Virol Methods (2011) 0.91
Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly(ethylene glycol)-block-poly(lactide-co-epsilon-caprolactone). J Biomed Mater Res B Appl Biomater (2009) 0.90
Presentation of lipopeptide by dendritic cells induces anti-tumor responses via an endocytosis-independent pathway in vivo. J Leukoc Biol (2011) 0.90
Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol (2013) 0.90
Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes Infect (2009) 0.89
Molecular visualization of the yeast Dmc1 protein ring and Dmc1-ssDNA nucleoprotein complex. Biochemistry (2005) 0.89
Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses. PLoS Negl Trop Dis (2012) 0.87
Mesenchymal stem cells promote neutrophil activation by inducing IL-17 production in CD4+ CD45RO+ T cells. Immunobiology (2012) 0.87
Rapid isolation and characterization of bacterial lipopeptides using liquid chromatography and mass spectrometry analysis. Proteomics (2011) 0.87
Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS One (2011) 0.86
HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins. Biochem Biophys Res Commun (2006) 0.86
Transgenic overexpression of anti-double-stranded DNA autoantibody and activation of Toll-like receptor 4 in mice induce severe systemic lupus erythematosus syndromes. J Autoimmun (2010) 0.86
A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol (2013) 0.86
A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One (2011) 0.85
Identification of novel vaccine candidates against Acinetobacter baumannii using reverse vaccinology. Hum Vaccin Immunother (2015) 0.84
Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS One (2012) 0.84
Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice. PLoS One (2013) 0.83
Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant. Pharm Res (2009) 0.83
Identification of synthetic vaccine candidates against SARS CoV infection. Biochem Biophys Res Commun (2007) 0.83
Generation and characterization of JSRV envelope transgenic mice in FVB background. Virology (2009) 0.83
Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness. PLoS One (2011) 0.83
Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch. Int J Nanomedicine (2012) 0.82
Cancer-targeted BikDD gene therapy elicits protective antitumor immunity against lung cancer. Mol Cancer Ther (2011) 0.82
Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. J Virol (2006) 0.82
Biochemical characterizations of Escherichia coli-expressed protective antigen Ag473 of Neisseria meningitides group B. Vaccine (2010) 0.81
Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Vaccine (2009) 0.81
Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. Cancer Biol Ther (2009) 0.81